Lorenz Frehner

Bern, BE 3010, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study.

LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study.

Journal: International urology and nephrology
Published: June 26, 2026

Germline HOXB13 G84E Variant in a Patient with Gastric and Prostate Cancer: A Case Report and Literature Review.

Germline HOXB13 G84E Variant in a Patient with Gastric and Prostate Cancer: A Case Report and Literature Review.

Journal: Case reports in oncology
Published: March 12, 2026

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases.

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 02, 2025

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

Journal: ESMO open
Published: July 11, 2025

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.

Journal: JTO clinical and research reports
Published: April 17, 2024

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer.

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Case reports in oncology
Published: May 25, 2023

Stereotactic Image-Guided Microwave Ablation for Malignant Liver Tumors-A Multivariable Accuracy and Efficacy Analysis.

Stereotactic Image-Guided Microwave Ablation for Malignant Liver Tumors-A Multivariable Accuracy and Efficacy Analysis.

Journal: Frontiers in oncology
Published: February 13, 2020

Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system.

Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system.

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: March 25, 2019
Showing 1-8 of 8

Last Updated: 09/26/2026